GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the use of Nucala, a monoclonal antibody that targets ...

(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China.

GSK (NYSE:GSK) announced that China's National Medical Products Administration has accepted its new drug application for Nucala (mepolizumab) as an add-on treatment for chronic obstructive pulmonary ...

(Alliance News) - GSK PLC on Thursday said its monoclonal ... Medical Products Administration accepted for review the new drug application for the use of Nucala for patients with chronic ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.99B ...

1. Rule 8 of the CGST Rules, 2017 has been amended to provide that an applicant can be identified on the common portal, based on data analysis and risk parameters for Biometric-based Aadhaar ...

If the Superior Court rejects the application to raise it to the Supreme Court, GSK and the other defendants ... and it was also sold in generic form by several other producers.

It has also been sold in generic form by several other producers, some of which have also been named in litigation, including Boehringer Ingelheim, Pfizer, and Johnson & Johnson. GSK's settlement ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 ...